Abbot receives CE Mark for Tecnis Symfony extended range of vision IOL

Article

Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

Abbott Park, IL-Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

According to Abbott, the Tecnics Symfony IOL is intended to provide a continuous range of vision, including far, intermediate, and near distances with reduced incidence of halo and glare comparable to a monofocal lens. The Tecnis Symfony IOL is not approved for use in the United States. 

Abbott began a 150-patient study in Europe to evaluate patients' quality of vision at far, intermediate, and near distances after being implanted in both eyes with the Tecnis Symfony IOL. The study will also assess both patient and surgeon satisfaction. Preliminary study results are anticipated later this year. The company is also conducting a post-market observational study with approximately 400 patients across Europe, including the United Kingdom, France, Germany, and Spain, with results expected at the end of 2014.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.